Holoclara Inc

Great to be featured in Labiotech.eu’s Best in Biotech series! Check out their article to learn how we’re decoding biology through metabolomics to pioneer worm-derived therapies: https://lnkd.in/gWBreY5Y

PharmaVoice’s crystal ball for 2025 featured our CEO Andrea Choe’s insights on how metabolomics will step into the spotlight and shape new breakthroughs in drug development. Check out the Year in Preview series: https://lnkd.in/et5482xq

Great to see our CEO Andrea Choe on stage at Caltech’s Merkin Institute Symposium. 🎙️ She shared insights from founding Holoclara alongside our advisor Brian Stoltz and local VC Nancy Hong, PhD. The event, hosted by Director of Merkin Institute for Translational Research, Viviana Gradinaru, was filled with inspiring ideas from fellow entrepreneurs, scientists, and leaders such as Karl Deisseroth.

🎧On the latest episode of the In Vivo Podcast, our CEO Andrea Choe spoke with host Tim Gabor, PhD about the incredible therapeutic potential of gut-dwelling roundworms. 🪱 Listen to their conversation for a deep dive into how these ancient creatures could in fact help protect our health – thanks to millions of years of co-evolution – and Holoclara's work harnessing worm-derived molecules to treat devastating disorders: https://lnkd.in/guHWM6KH #Worms #WormScience #WormTherapies #Allergies #Autoimmune #Biotech

What’s in store for biotech in 2025? Our CEO Andrea Choe shared her expectations for the impact and expansion of #metabolomics with Labiotech.eu 👇 “Just as CRISPR and GLP-1 drugs revolutionized genetic and metabolic therapies, metabolomics will further unlock novel strategies that match the complexity of human biology … guiding us into an era of truly customized medicine.” Read the article for more on this trend that could transform the biotech industry:  https://lnkd.in/dZrDAdhM #WormTherapies #WormsAsMedicine #Biotech 

Fierce Biotech highlighted the start of our clinical trials for HC002, a first-in-class worm-derived therapy. Read the article to learn more about our Phase 1 study and lead indication, eosinophilic esophagitis (EoE): https://lnkd.in/giVx9zTY Thanks to Darren Incorvaia for speaking with our co-founder and CEO Andrea Choe about our work to harness molecules identified in worms for breakthrough medicines, plan to expand to other critical indications, and more.

We’re pleased to announce our first-in-human Phase 1 clinical trial of HC002 – a novel worm-derived medicine – and eosinophilic esophagitis (EoE) as our lead indication. 💊 More on HC002 and our Phase 1 study: - An investigational, orally bioavailable small molecule therapy harnessing the therapeutic potential of worms to address historically untreatable diseases - Study testing the safety and tolerability of HC002 in healthy adults will be conducted in partnership with Novotech and CMAX Clinical Research 🩺 On EoE:  -  Chronic inflammatory disorder historically considered to be an orphan disease  - Rapid increase in prevalence to 1 in 700 people in the U.S. today makes it the second most common esophageal disease Check out the video and press releases below to learn more about our clinical progress from our CEO Andrea Choe, CMAX CEO Jane Kelly, principal investigator Thomas Polasek and Evan S. Dellon, leading gastroenterologist at the University of North Carolina at Chapel Hill School of Medicine. 🔗 Phase 1 press release (https://lnkd.in/g4ZMheam) and study details (https://lnkd.in/gwC6quXU) 🔗 Indication press release (https://lnkd.in/g6BF_tEs) #Worms #WormScience #WormTherapies #WormsAsMedicine #Allergies #Autoimmune #EosinophilicEsophagitis #Biotech #ClinicalTrials

In an interview with Pulse 2.0 editor in chief Amit Chowdhry, our co-founder and CEO Andrea Choe discusses our latest milestones, technology, and at the core of it all – our commitment to translating breakthrough science into solutions for patients. Give it a read 👉 https://lnkd.in/gdjb4Mtj #Worms #WormScience #WormTherapies #WormsAsMedicine #Allergies #Autoimmune #Biotech

📢 Holoclara has been selected as the winner of the Immunomodulatory Solution of the Year by the BioTech Breakthrough Awards! We’re proud to be developing first-in-class worm-derived therapies that could serve as breakthrough treatments for allergic and autoimmune disease. Read the full announcement 👉 https://lnkd.in/gYXC6PQ5 #WormScience #WormsAsMedicine #Worms #WormTherapies #Allergies #Autoimmune #Biotech

A scientist and a reporter walk into a worm lab. If this is a story you haven’t heard before, check out Allie Garfinkle’s recent feature in Fortune interviewing our co-founders, CEO Andrea Choe and advisor Paul Sternberg, and one of our investors, Neal Bhadkamkar at BOLD Capital Partners. They discuss worm behavior, their long evolutionary history with humans, and how it all led to our development of breakthrough worm-derived therapies. Bonus: Learn why some worms are called “dumpys” or “uncs.” 👉 https://lnkd.in/g-bQq4-g